Value, affordability and decision making

News
March 2018

Value Frameworks: Value in Health Special Issue

News
March 2018

Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Economics of Innovation

2017 OHE Annual Report to the Charity Commission

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Real World Evidence for Coverage Decisions: Opportunities and Challenges

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions

News
November 2017

OHE at ISPOR’s 20th Annual European Congress in Glasgow

00
11
12
13
14
15
16
17
18
19
00

Latest Research & Publications

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

The UK Biotech Sector and Brexit: Past Performance and Future Prospects

New Methods for Analysing the Distribution of EQ-5D Observations

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions

Real World Evidence for Coverage Decisions: Opportunities and Challenges

All Publications

Filter results by

Filter results by

Value Frameworks: Value in Health Special Issue

Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

2017 OHE Annual Report to the Charity Commission

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Real World Evidence for Coverage Decisions: Opportunities and Challenges

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions

OHE at ISPOR’s 20th Annual European Congress in Glasgow

Share on Mastodon